We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Rapid Results Achieved with Handheld Diagnostic Platform

By LabMedica International staff writers
Posted on 19 Mar 2013
A functional prototype of a new handheld system for on-the-spot diagnostic results has been completed.

The AgPlus Diagnostics (Bedfordshire, United Kingdom) platform utilizes electrochemical immunoassay technology in a microfluidic chip format. More...
The signalling and measurement system, based on the detection of amplified silver ions by anodic stripping voltammetry, allows sensitive, accurate, and quantifiable results to be obtained from a small sample volume (50 µL) within minutes. No sample preparation is required, making it ideal for multiple sample types and for testing in a range of settings.

The AgPlus technology prototype demonstrates an assay for human Troponin I, a cardiac marker used in clinical settings. The AgPlus Troponin I assay is currently showing a dynamic range of 0.1–50 ng/mL in a nonoptimized format with assay run times of 10 minutes. AgPlus tests for cortisol and testosterone are being developed, which will be applicable in sports science applications.

Via a portable handheld device (with WiFi and Bluetooth technology for storage and communication of results), AgPlus technology offers fully quantitative laboratory-equivalent analysis of multiple analytes from a single sample.

“The first working AgPlus technology system prototype is an important milestone for AgPlus Diagnostics, demonstrating the successful coming together of this novel diagnostic assay and its unique analytical platform to achieve a fully functional, portable system that can deliver accuracy and sensitivity that’s on a par with laboratory analyzers,” commented Keith Page, CEO of Agplus Diagnostics.

Related Links:
AgPlus Diagnostics


Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Benchtop Thermomixer
Biometra TS1 ThermoShaker
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers use a novel immobilized liposome-bound gel beads method to measure CEC levels and their association with cardiovascular risks (Photo courtesy of Institute of Science Tokyo)

Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features

Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.